A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 137,500 shares of CAPR stock, worth $3.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
137,500
Previous 53,150 158.7%
Holding current value
$3.02 Million
Previous $361,000 81.44%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$4.63 - $7.09 $390,540 - $598,041
84,350 Added 158.7%
137,500 $655,000
Q1 2024

May 13, 2024

SELL
$3.61 - $6.88 $336,347 - $641,016
-93,171 Reduced 63.68%
53,150 $361,000
Q4 2023

Feb 13, 2024

BUY
$2.71 - $5.08 $281,027 - $526,796
103,700 Added 243.31%
146,321 $716,000
Q3 2023

Nov 14, 2023

SELL
$3.42 - $7.85 $12,996 - $29,830
-3,800 Reduced 8.19%
42,621 $146,000
Q2 2023

Aug 11, 2023

BUY
$3.76 - $5.05 $59,784 - $80,295
15,900 Added 52.1%
46,421 $222,000
Q1 2023

May 12, 2023

BUY
$3.78 - $5.03 $28,350 - $37,725
7,500 Added 32.58%
30,521 $129,000
Q4 2022

Feb 13, 2023

BUY
$3.36 - $6.55 $43,078 - $83,977
12,821 Added 125.7%
23,021 $89,000
Q3 2022

Nov 14, 2022

BUY
$3.61 - $6.08 $36,822 - $62,016
10,200 New
10,200 $61,000
Q3 2020

Nov 13, 2020

SELL
$4.08 - $9.81 $811,104 - $1.95 Million
-198,800 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$1.0 - $8.5 $95,185 - $809,072
95,185 Added 91.86%
198,800 $914,000
Q1 2020

May 14, 2020

BUY
$0.94 - $2.02 $18,640 - $40,056
19,830 Added 23.67%
103,615 $124,000
Q4 2019

Feb 13, 2020

BUY
$1.04 - $3.55 $45,002 - $153,615
43,272 Added 106.81%
83,785 $107,000
Q3 2019

Nov 13, 2019

BUY
$2.38 - $6.23 $96,420 - $252,395
40,513 New
40,513 $150,000

Others Institutions Holding CAPR

About CAPRICOR THERAPEUTICS, INC.


  • Ticker CAPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,346,200
  • Market Cap $535M
  • Description
  • Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...
More about CAPR
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.